

Metacam 2.5 mg Chewable Tablets for Dogs  
APVMA 60536  
ACVM A9630  
Page 1 of 5  
21 May 2013

Blister

**FOR ANIMAL TREATMENT ONLY**

Metacam<sup>®</sup> 2.5 mg Chewable Tablets for Dogs

Meloxicam

Batch No.:

Expiry:



Metacam 2.5 mg Chewable Tablets for Dogs

APVMA 60536

ACVM A9630

Page 2 of 5

21 May 2013

Carton Label

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

Metacam<sup>®</sup> 2.5 mg Chewable Tablets for Dogs

Active Constituent:  
Meloxicam 2.5 mg per tablet

7 tablets (84 tablets, 252 tablets)

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

**READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT.**

**Directions for Use**

**Contraindicated for use in bitches in the last third of pregnancy or during lactation.**

**Contraindicated for use in dogs less than 6 weeks of age or less than 4 kg bodyweight.**

Single dose on the first day: 0.2 mg meloxicam/kg bodyweight.

Maintenance dose: 0.1 mg meloxicam/kg bodyweight once daily (1 chewable tablet per 25 kg bodyweight).

**Disposal**

Dispose of empty container by wrapping in paper and putting in garbage.

Store below 30°C (Room Temperature).

**Australia**

Boehringer Ingelheim Pty Limited  
Animal Health Division  
78 Waterloo Road  
North Ryde NSW 2113

APVMA 60536/59881

**New Zealand**

Boehringer Ingelheim (NZ) Limited  
Animal Health Division  
Level 1, Unit 9  
42 Ormiston Road  
East Tamaki Auckland

**Restricted Veterinary Medicine. A9630**

See [www.foodsafety.govt.nz](http://www.foodsafety.govt.nz) for registration conditions.

Batch No.:

Expiry:

Leaflet

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

**METACAM®**

**1 mg Chewable Tablets for Dogs  
2.5 mg Chewable Tablets for Dogs**

**Composition**

1 mg tablet contains 1 mg meloxicam  
2.5 mg tablet contains 2.5 mg meloxicam

**Action**

Meloxicam is a non-steroidal anti-inflammatory compound of the oxicam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leukocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen-induced thrombocyte aggregation.

**Indications**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

**DIRECTIONS FOR USE**

**Contraindications**

**Contraindicated for use in bitches in the last third of pregnancy or during lactation.  
Contraindicated for use in dogs less than 6 weeks of age or less than 4 kg bodyweight.  
Contraindicated in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders or individual hypersensitivity to the product.**

**Precautions**

Metacam® should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics or anti-coagulant agents. Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Metacam®. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously. Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is potential risk of increased renal toxicity.

**Side Effects**

Typical adverse reactions of NSAIDs may occur (particularly within the first 5-14 days of treatment). These may include loss of appetite, vomiting, diarrhoea, faecal occult blood and lethargy. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

**Overdose**

In case of overdosing a symptomatic treatment should be initiated.

**Dosage and Administration**

Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day, which can be given orally or alternatively using Metacam<sup>®</sup> Anti-inflammatory Injectable for Dogs and Cats.

Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight. Each chewable tablet contains either 1.0 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg bodyweight dog or a 25 kg bodyweight dog respectively. Each chewable tablet can be halved for accurate dosing according to the individual bodyweight of the animal. Metacam<sup>®</sup> chewable tablets can be administered with or without food, are flavoured and are taken by dogs voluntarily.

Dose scheme for the maintenance dose:

Bodyweight (kg)	Number of chewable tablets		mg/kg
	1 mg	2.5 mg	
4.0-7.0	½		0.13-0.1
7.1-10.0	1		0.14-0.1
10.1-15.0	1 ½		0.15-0.1
15.1-20.0	2		0.13-0.1
20.1-25.0		1	0.12-0.1
25.1-35.0		1 ½	0.15-0.1
35.1-50.0		2	0.14-0.1

Use of Metacam<sup>®</sup> Oral Suspension for Dogs should be considered for animals where more precise dosing is indicated. For dogs weighing less than 4 kg the use of Metacam<sup>®</sup> Oral Suspension for Dogs is recommended.

Metacam 2.5 mg Chewable Tablets for Dogs

APVMA 60536

ACVM A9630

Page 5 of 5

21 May 2013

A clinical response is normally seen within 3-4 days. If no improvement is seen after 10 days of treatment, discontinue use and consult your veterinary surgeon.

**First Aid**

If poisoning occurs, contact a doctor or Poisons Information Centre. *Phone Australia 131126; New Zealand 0800 764 766 (0800 POISON).*

**Disposal**

Dispose of empty container by wrapping with paper and putting in garbage.

**Storage**

Store below 30°C (Room Temperature).

**Presentation**

7 tablets (blister)

84 tablets (blister)

252 tablets (blister)

Not all pack sizes may be marketed.

**Australia**

Boehringer Ingelheim Pty Limited

Animal Health Division

78 Waterloo Road

North Ryde NSW 2113

**APVMA 60535/59841**

**New Zealand**

Boehringer Ingelheim (NZ) Limited

Animal Health Division

Level 1, Unit 9

42 Ormiston Road

East Tamaki Auckland

**Restricted Veterinary Medicine.** A9630; A9631

See [www.foodsafety.govt.nz](http://www.foodsafety.govt.nz) for registration conditions.